Terminated PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT02068521

Versartis Long-Term Safety Study of Somavaratan (VISTA)

An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency

Sponsor: Versartis Inc.

Conditions Pediatric Growth Hormone Deficiency

Interventions somavaratan

Updated 11 times since 2017 Last updated: Mar 7, 2018 Started: Mar 3, 2014 Primary completion: Nov 17, 2017 Completion: Nov 17, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The primary endpoint of non-inferiority to daily therapy in the pediatric Phase 3 study was not achieved

Other terminated trials from Versartis Inc.

More terminations from Versartis Inc.

This PHASE2/PHASE3 trial investigates Pediatric Growth Hormone Deficiency and is currently terminated or withdrawn. Versartis Inc. leads this study, which shows 11 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE2_PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2_PHASE3
Nov 2020 — Jan 2021 [monthly]

Terminated PHASE2_PHASE3

▶ Show 6 earlier versions

Jun 2018 — Nov 2020 [monthly]

Terminated PHASE2_PHASE3
May 2018 — Jun 2018 [monthly]

Terminated PHASE2_PHASE3
Mar 2018 — May 2018 [monthly]

Terminated PHASE2_PHASE3

Status: Active Not Recruiting → Terminated
Dec 2017 — Mar 2018 [monthly]

Active Not Recruiting PHASE2_PHASE3

Status: Recruiting → Active Not Recruiting
Feb 2017 — Dec 2017 [monthly]

Recruiting PHASE2_PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Versartis Inc.

Data source: Versartis Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.